Parabilis Medicines, Inc. (NASDAQ:PBLS – Get Free Report) Director Alan Sebulsky acquired 8,435 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were bought at an average cost of $27.67 per share, with a total value of $233,396.45. Following the completion of the acquisition, the director directly owned 20,935 shares in the company, valued at approximately $579,271.45. This represents a 67.48% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Alan Sebulsky also recently made the following trade(s):
- On Monday, June 15th, Alan Sebulsky acquired 9,065 shares of Parabilis Medicines stock. The stock was bought at an average cost of $26.49 per share, with a total value of $240,131.85.
- On Thursday, June 11th, Alan Sebulsky bought 12,500 shares of Parabilis Medicines stock. The stock was bought at an average price of $20.00 per share, for a total transaction of $250,000.00.
Parabilis Medicines Stock Down 0.7%
PBLS stock opened at $25.85 on Friday. Parabilis Medicines, Inc. has a twelve month low of $24.51 and a twelve month high of $34.47.
Featured Stories
- Five stocks we like better than Parabilis Medicines
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
